title: Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.
authors.forename: Mark
authors.initials: M
authors.lastname: Sculpher
mesh_terms: D000077556:Alitretinoin; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D000068818:Cetuximab; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D003879:Dermatologic Agents / Q000191:economics / Q000627:therapeutic use; D004485:Eczema / Q000188:drug therapy / Q000191:economics; D019317:Evidence-Based Medicine; D035082:Federal Government; D006229:Hand Dermatoses / Q000188:drug therapy / Q000191:economics; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000191:economics; D006801:Humans; D038622:Internationality; D009313:National Health Programs; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy / Q000191:economics; D010380:Peer Review; D019057:Quality-Adjusted Life Years; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014212:Tretinoin / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D000077556:Alitretinoin; D014212:Tretinoin; D000068818:Cetuximab
references.citation: Pharmacoeconomics. 2010;28(2):143-52
references.pmid: 20085390
references.citation: Pharmacoeconomics. 2008;26(12):1037-43
references.pmid: 19014204
references.citation: Pharmacoeconomics. 2010;28(2):93-102
references.pmid: 20085386
references.citation: Pharmacoeconomics. 2010;28(2):153-62
references.pmid: 20085391
references.citation: Pharmacoeconomics. 2010;28(2):109-11
references.pmid: 20085388
references.citation: Pharmacoeconomics. 2010;28(2):105-7
references.pmid: 20085387
references.citation: Pharmacoeconomics. 2010;28(5):351-62
references.pmid: 20131924
references.citation: Health Policy. 2008 Sep;87(3):389-400
references.pmid: 18387689
references.citation: Pharmacoeconomics. 2010;28(2):163-70
references.pmid: 20085392
references.citation: Value Health. 2009 Mar-Apr;12(2):193-201
references.pmid: 18700865
references.citation: Pharmacoeconomics. 2010;28(2):113-42
references.pmid: 20085389
references.citation: Pharmacoeconomics. 2010;28(6):439-48
references.pmid: 20465313